Skip to main content
Equibles

Ikarian Capital, LLC

Position in NXTC — NextCure, Inc.

CIK 1778253 DALLAS, TX
Back to NXTC Full portfolio

Position in NXTC

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$461,284
-$2,083,792 QoQ
Shares Held
288,303
+21.0% QoQ
Ownership
6.30%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#1
of 30 holders
Holding Since
Mar 2020
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NXTC Over Time

Shares Held

Position Value (USD)

Derivatives in NXTC

reported options exposure · as of Mar 31, 2020
CallValue
$0
CallShares
0
PutValue
$1,508,748
PutShares
3,392

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. NXTC ranks #83 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 328,635 $43,793,900
2 KOD
Kodiak Sciences Inc.
 1,059,730 $41,287,080
3 ALMS
Alumis Inc.
 870,548 $24,497,220
4 PRAX
Praxis Precision Medicines, Inc.
 72,842 $24,386,773
5 PCVX
Vaxcyte, Inc.
 388,682 $22,594,084
6 CLDX
Celldex Therapeutics, Inc.
 478,500 $17,804,985
7 RCUS
Arcus Biosciences, Inc.
 504,559 $15,555,553
8 RLMD
Relmada Therapeutics, Inc.
 2,148,359 $14,866,644

All Filings in NXTC

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $461,284 288,303
2026-03-31 $2,545,076 238,303
2025-12-31 $3,381,519 238,303
2022-06-30 $335,744 71,435
2022-03-31 $685,541 141,058
2021-12-31 $804,329 134,055
2021-09-30 $3,431,704 509,155
2021-06-30 $4,150,466 516,870
2021-03-31 $4,544,059 453,952
2020-12-31 $2,179,999 200,000
2020-09-30 $1,759,999 200,000
2020-03-31 $1,508,748 40,700